Qin Jianru, Lin Jilei, Zhang Xiangfei, Yuan Shuhua, Zhang Chiyu, Yin Yong
NMPA Key Laboratory for Research and Evaluation of Innovative Drug, College of Life Sciences, Henan Normal University, Xinxiang, China.
Department of Respiratory, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Pharmacol. 2022 Apr 6;13:849545. doi: 10.3389/fphar.2022.849545. eCollection 2022.
To estimate the clinical effectiveness of oseltamivir in children with different subtypes of influenza virus infection. A total of 998 children with acute respiratory infection were enrolled from January to March 2018, and were divided into influenza A, influenza B, influenza A + B, and non-influenza infection (IV-negative) groups. Influenza-like symptoms and duration of fever were evaluated and compared between oseltamivir-treated and non-treated groups. There were no significant differences in the reduction in total febrile period and duration of fever from the onset of therapy between the oseltamivir treated and non-treated children infected with influenza A ( = 0.6885 for total febrile period and 0.7904 for the duration of fever from the onset of treatment), influenza B ( = 0.1462 and 0.1966), influenza A + B ( = 0.5568 and 0.9320), and IV-negative ( = 0.7631 and 0.4655). The duration of fever in children received oseltamivir therapy within 48 h was not significantly shorter than that beyond 48 h ( > 0.05). Additionally, percentages and severities of influenza-like symptoms, including headache, myalgia, fatigue, bellyache, vomiting, diarrhea, sore throat, cough, and coryza were not decreased and alleviated after treatment of oseltamivir. Oseltamivir treatment does not significantly shorten the duration of fever, nor does it significantly relieve influenza-like symptoms in children with infection of influenza.
评估奥司他韦对不同亚型流感病毒感染儿童的临床疗效。2018年1月至3月共纳入998例急性呼吸道感染儿童，分为甲型流感、乙型流感、甲型+乙型流感和非流感感染（流感病毒检测阴性）组。对接受奥司他韦治疗和未治疗的组进行流感样症状和发热持续时间的评估与比较。在甲型流感感染儿童（治疗开始后总发热期的P = 0.6885，发热持续时间的P = 0.7904）、乙型流感感染儿童（P = 0.1462和0.1966）、甲型+乙型流感感染儿童（P = 0.5568和0.9320）以及流感病毒检测阴性儿童（P = 0.7631和0.4655）中，奥司他韦治疗组和未治疗组在治疗开始后总发热期缩短情况及发热持续时间方面均无显著差异。在48小时内接受奥司他韦治疗的儿童发热持续时间并不显著短于48小时后接受治疗的儿童（P>0.05）。此外，奥司他韦治疗后，包括头痛、肌痛、疲劳、腹痛、呕吐、腹泻、咽痛、咳嗽和鼻塞等流感样症状的发生率和严重程度并未降低和缓解。奥司他韦治疗并不能显著缩短流感感染儿童的发热持续时间，也不能显著缓解其流感样症状。
